Early results with the LARIAT device for left atrial appendage exclusion in patients with atrial fibrillation at high risk for stroke and anticoagulation

Catheterization and Cardiovascular Interventions

Volumn 86, Issue 1, 2015, Pages 121-127

  Stone, Diana ^a   Byrne, Timothy ^a   Pershad, Ashish ^a  

^a BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

Author keywords

cerebrovascular accident; left atrial appendage closure

Indexed keywords

ACETYLSALICYLIC ACID; DABIGATRAN; PURINERGIC RECEPTOR BLOCKING AGENT; RIVAROXABAN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CLINICAL ARTICLE; FEMALE; FLUOROSCOPY; FOLLOW UP; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MALE; OBSERVATIONAL STUDY; PERCUTANEOUS LEFT ATRIAL APPENDAGE EXCLUSION; PERICARDITIS; PLEURA EFFUSION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; UROLOGICAL SNARE; BALLOON OCCLUSION; COLOR DOPPLER ECHOCARDIOGRAPHY; COMPLICATION; DEVICES; ECHOGRAPHY; HEART ATRIUM APPENDAGE; HEART SURGERY; LIGATION; MIDDLE AGED; RADIOGRAPHY; STROKE; SUTURE; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; BALLOON OCCLUSION; CARDIAC SURGICAL PROCEDURES; ECHOCARDIOGRAPHY, DOPPLER, COLOR; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; FLUOROSCOPY; FOLLOW-UP STUDIES; HUMANS; LIGATION; MALE; MIDDLE AGED; STROKE; SUTURES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84931957495     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.25065     Document Type: Article

References (34)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE,. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
2. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC, Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL,. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006; 48: 854-906.
3. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS,. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-125.
4. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ,. Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 2004; 110: 1042-1046.
5. Wolf PA, Abbott RD, Kannel WB,. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983-988.
6. Stewart S, Hart CL, Hole DJ, McMurray JJ,. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359-364.
7. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D,. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98: 946-952.
8. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
9. Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force. Arch Neurol 1989; 46: 727-743.
10. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ,. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
11. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ,. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest 2010; 137: 263-272.
12. Britton M, Gustafsson C,. Non-rheumatic atrial fibrillation as a risk factor for stroke. Stroke 1985; 16: 182-188.
13. Stafford RS, Singer DE,. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998; 97: 1231-1233.
14. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L,. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
15. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE,. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131: 927-934.
16. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L,. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
17. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM,. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
18. Hughes M, Lip GY,. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: A systematic review. QJM 2007; 100: 599-607.
19. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY,. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010; 138: 1093-1100.
20. Blackshear JL, Odell JA,. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996; 61: 755-759.
21. Johnson WD, Ganjoo AK, Stone CD, Srivyas RC, Howard M,. The left atrial appendage: Our most lethal human attachment! Surgical implications. Eur J Cardiothorac Surg 2000; 17: 718-722.
22. Katz ES, Tsiamtsiouris T, Applebaum RM, Schwartzbard A, Tunick PA, Kronzon I,. Surgical left atrial appendage ligation is frequently incomplete: A transesophageal echocardiographic study. J Am Coll Cardiol 2000; 36: 468-471.
23. Garcia-Fernandez MA, Perez-David E, Quiles J, Peralta J, Garcia-Rojas I, Bermego J, Moreno M, Silva J,. Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: A transesophageal echocardiographic study. J Am Coll Cardiol 2003; 42: 1253-1258.
24. Blackshear JL, Johnson WD, Odell JA, Baker VS, Howard M, Pearce L, Stone C, Packer DL, Schaff HV,. Thoracoscopic extracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation. J Am Coll Cardiol 2003; 42: 1249-1252.
25. Pennec PY, Jobic Y, Blanc JJ, Bezon E, Barra JA,. Assessment of different procedures for surgical left atrial appendage exclusion. Ann Thorac Surg 2003; 76: 2168-2169.
26. Healey JS, Crystal E, Lamy A, Teoh K, Semelhago L, Hohnloser SH, Cybulsky I, et al., Left Atrial Appendage Occlusion Study (LAAOS): Results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J 2005; 150: 288-293.
27. Schneider B, Stollberger C, Sievers HH,. Surgical closure of the left atrial appendage-A beneficial procedure? Cardiology 2005; 104: 127-132.
28. Kanderian AS, Gillinov AM, Pettersson GB, Blackstone E, Klein AL,. Success of surgical left atrial appendage closure: Assessment by transesophageal echocardiography. J Am Coll Cardiol 2008; 52: 924-929.
29. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P,. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: A randomised non-inferiority trial. Lancet 2009; 374: 534-542.
30. Park JW, Bethencourt A, Sievert H, Santoro G, Meier B, Walsh K, Lopez-Minquez JR, Meerkin D, Valdés M, Ormerod O, Leithäuser B,. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: Initial European experience. Catheter Cardiovasc Interv 2011; 77: 700-706.
31. Lee RJ, Bartus K, Yakubov SJ,. Catheter-based left atrial appendage (LAA) ligation for the prevention of embolic events arising from the LAA initial experience in a canine model. Circ Cardiovasc Interv 2010; 3: 224-229.
32. Singh SM, Dukkipati SR, d'Avila A, Doshi SK, Reddy VY,. Percutaneous left atrial appendage closure with an epicardial suture ligation approach: A prospective randomized pre-clinical feasibility study. Heart Rhythm 2010; 7: 370-376.
33. Bartus K, Han F, Bednarek J, Myc J, Kapelak B, Sadowski J, Lelakowski J, Yakubov SJ, Lee RJ,. Percutaneous left atrial appendage suture ligation using the LARIAT in patients with atrial fibrillation: Initial clinical experience. J Am Coll Cardiol 2013; 62: 108-118.
34. Massumi A, Chelu MG, Nazeri A, May S, Afshar-Kharaghan H, Saeed M, Razavi M, Rasekh A., Initial experience with a novel percuatnaeous left atrial appendage exclusion device in patients with atrial fibrillation, increased stroke risk, and contraindications to anticoagualation. Am J Cardiol 2013; 111: 869-873.